Article Text
Statistics from Altmetric.com
With great interest, we read the comment of our colleagues from the UK on our recent viewpoint,1 and we appreciate that they largely agree with us.2 This is a bit different in a recent review on the same topic,3 which argues that it is still possible that anti-IL23 agents work for axial psoriatic arthritis (PsA). Nevertheless, our colleagues from the UK raise two important points, which we like to shortly comment on.
First, the important factor of age is discussed, which plays an important role in the frequent clinical situation of patients presenting to the doctor because of acute or chronic back pain—simply because the prevalence of degenerative changes in the axial skeleton does increase with age,4 5 and axial spondyloarthritis (axSpA) starts most often in the third decade of life6 …
Footnotes
Handling editor Josef S Smolen
Contributors Both authors have equally contributed.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Commissioned; internally peer reviewed.